Cardiovascular Medicine

2 pages, 393 KB

Open AccessInteresting Images

by Olivier Roux, Francine Tinguely, Jean-Luc Barras, René Prêtre and Jean-Jacques Goy

Cardiovasc. Med. 2017, 20(5), 136; https://doi.org/10.4414/cvm.2017.00474 - 17 May 2017

Cited by 2 | Viewed by 10

An 16-year-old male patient with a family history of hypertrophic obstructive cardiomyopathy was referred for screening echocardiograph [...] Full article

4 pages, 1158 KB

Open AccessCase Report

Ciment Posé, Pas D’anxiété—Ciment Pulmonaire, Faut-il S’en Faire?

by Matthieu Kolly, Samuel Kolly, Leopold Schlueter, Yvan Fleury, Nicolas Brugger, Gianluca Maestretti and Stéphane Cook

Cardiovasc. Med. 2017, 20(5), 132; https://doi.org/10.4414/cvm.2017.00480 - 17 May 2017

Viewed by 10

Abstract

The right heart and the pulmonary vascular tree are at risk of embolization of nonthrombotic material. With the development of sealing resin in all surgical specialties, the risk of vascular embolization of glue during polymerization increases. We describe the presentation, management and clinical [...] Read more.

The right heart and the pulmonary vascular tree are at risk of embolization of nonthrombotic material. With the development of sealing resin in all surgical specialties, the risk of vascular embolization of glue during polymerization increases. We describe the presentation, management and clinical follow- up of three patients with symptomatic cement embolization following a vertebroplasty. Cement emboli are a frequent complication of vertebroplasty, which rarely requires specific management. Full article

9 pages, 198 KB

Open AccessReview

PCSK9-Hemmung mit Antikörpern: Die Resultate der Phase-III-Studienprogramme

by François Mach, Georg Noll, Walter F. Riesen and Isabella Sudano

Cardiovasc. Med. 2017, 20(5), 123; https://doi.org/10.4414/cvm.2017.00482 - 17 May 2017

Cited by 1 | Viewed by 10

Abstract

The approval of PCSK9 inhibitors has led to a substantial increase of therapeutic options in the management of blood lipid levels. This is especially important for high-risk patients and patients with familiar hyperlipidemia, who cannot achieve adequate LDL-C lowering with other lipid lowering [...] Read more.

The approval of PCSK9 inhibitors has led to a substantial increase of therapeutic options in the management of blood lipid levels. This is especially important for high-risk patients and patients with familiar hyperlipidemia, who cannot achieve adequate LDL-C lowering with other lipid lowering therapies. In the PROFICIO study program, the fully human anti-PSCK9 antibody evolocumab led to a significant reduction of LDL-C. Good tolerability and a significant reduction in LDL-C levels were maintained during long-term treatment. In addition, a reduction in cardiovascular events compared to standard therapy was noted. A significant reduction of LDL-C was also observed during the ODYSSEY study program with the fully human anti-PCSK9 antibody alirocumab. Combination therapy with statins or other lipid lowering treatment or monotherapy with both antibodies were well tolerated. A post hoc analysis of long-term data showed preliminary evidence for positive effects on cardiovascular risk. The data of the prospective randomised FOURIER study showed a significant reduction of the clinical outcomes. The ODYSSEY Outcomes study will provide further insights in the future. Bococizumab, a humanized anti-PCSK9 antibody similarly showed a significant benefit in high risk patients in SPIRE, but not in SPIRE 1 with low risk patients. However, the SPIRE-2 program was prematurely terminated. Because of undesired side effects. Full article

6 pages, 167 KB

Open AccessCommunication

Data Sharing: A New Editorial Initiative of the International Committee of Medical Journal Editors

by Fernando Alfonso, Karlen Adamyan, Jean-Yves Artigou, Michael Aschermann, Michael Boehm, Alfonso Buendia, Pao-Hsien Chu, Ariel Cohen, Livio Dei Cas, Mirza Dilic, Anton Doubell, Dario Echeverri, Nuray Enç, Ignacio Ferreira-González, Krzysztof J. Filipiak, Andreas Flammer, Eckart Fleck, Plamen Gatzov, Carmen Ginghina, Lino Goncalves, Habib Haouala, Mahmoud Hassanein, Gerd Heusch, Kurt Huber, Ivan Hulín, Mario Ivanusa, Rungroj Krittayaphong, Chu-Pak Lau, Germanas Marinskis, François Mach, Luiz Felipe Moreira, Tuomo Nieminen, Latifa Oukerraj, Stefan Perings, Luc Pierard, Tatjana Potpara, Walter Reyes-Caorsi, Se-Joong Rim, Olaf Rødevand, Georges Saade, Mikael Sander, Evgeny Shlyakhto, Bilgin Timuralp, Dimitris Tousoulis, Dilek Ural, J. J. Piek, Albert Varga and Thomas F. Lüscher Show full author list Hide full author list

Cardiovasc. Med. 2017, 20(5), 117; https://doi.org/10.4414/cvm.2017.00477 - 17 May 2017

Viewed by 13

Abstract

The International Committee of Medical Journal Editors (ICMJE) provides recommendations to improve the editorial standards and scientific quality of biomedical journals. These recommendations range from uniform technical requirements to more complex and elusive editorial issues including ethical aspects of the scientific process. Recently, [...] Read more.

The International Committee of Medical Journal Editors (ICMJE) provides recommendations to improve the editorial standards and scientific quality of biomedical journals. These recommendations range from uniform technical requirements to more complex and elusive editorial issues including ethical aspects of the scientific process. Recently, registration of clinical trials, conflicts of interest disclosure, and new criteria for authorship – emphasising the importance of responsibility and accountability –, have been proposed. Last year, a new editorial initiative to foster sharing of clinical trial data was launched. This review discusses this novel initiative with the aim of increasing awareness among readers, investigators, authors and editors belonging to the Editors´ Network of the European Society of Cardiology. Full article

2 pages, 157 KB

Open AccessCommunication

In Memoriam: Prof. Dr. Fritz R. Bühler

by Thomas F. Lüscher, Paul Erne, Felix Gutzwiller, Therese J. Resink, Regine Landmann, Zhihong Yang and Ruth Amstein

Cardiovasc. Med. 2017, 20(5), 115; https://doi.org/10.4414/cvm.2017.00483 - 17 May 2017

Viewed by 9

Abstract

Am 5. April 2017 ist Fritz R. Bühler für viele überraschend verstorben. Die Familie, seine ehemaligen Mitarbeiter und die kardiovaskuläre Medizin trauern um einen grossen Forscher, engagierten Arzt und umsichtigen Mentor [...] Full article

4 pages, 319 KB

Open AccessEditorial

Gibt es Dogmen in der Medizin?

by Thomas F. Lüscher

Cardiovasc. Med. 2017, 20(5), 111; https://doi.org/10.4414/cvm.2017.00484 - 17 May 2017

Viewed by 10

Abstract

Was ist ein Dogma?
Wenn wir unseren Freund Wikipedia konsultieren, so versteht man unter einem Dogma, altgriechisch δόγμα, eine Meinung, einen Lehrsatz, Beschluss oder eine Verordnung, eine grundlegende Aussage also, deren Wahrheitsanspruch als unumstösslich gilt – man denkt sogleich an religiöse Aussagen [...] [...] Read more.

Was ist ein Dogma?
Wenn wir unseren Freund Wikipedia konsultieren, so versteht man unter einem Dogma, altgriechisch δόγμα, eine Meinung, einen Lehrsatz, Beschluss oder eine Verordnung, eine grundlegende Aussage also, deren Wahrheitsanspruch als unumstösslich gilt – man denkt sogleich an religiöse Aussagen [...] Full article

5 pages, 215 KB

Open AccessEditorial

Cardiology Update 2017: Postgraduate Education at the Highest Level

by Ruth Amstein

Cardiovasc. Med. 2017, 20(5), 1; https://doi.org/10.4414/cvm.2017.00479 - 17 May 2017

Viewed by 9

Abstract

Cardiology Update is one of the major meetings in the field of cardiology in Europe [...] Full article

Journal Menu

Journal Browser

Cardiovasc. Med., Volume 20, Issue 5 (05 2017) – 7 articles

Further Information

Guidelines

MDPI Initiatives

Follow MDPI